IDEAYA Biosciences vs Syndax Pharmaceuticals
IDEAYA Biosciences reported revenue of $219 million in fiscal 2025, 1.3 times Syndax Pharmaceuticals' $172 million in fiscal 2025. IDEAYA Biosciences' revenue grew 3024.4% in its latest year, and Syndax Pharmaceuticals' grew 627.8%. IDEAYA Biosciences had an operating margin of -72.8%, against -158.4% at Syndax Pharmaceuticals. Free cash flow was −$73 million at IDEAYA Biosciences and −$323 million at Syndax Pharmaceuticals.
Side by side
| IDEAYA Biosciences | Syndax Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $219M | $172M |
| Revenue growth | 3,024.4% | 627.8% |
| Revenue growth a year, last 5 years | 62.2% | 158.3% |
| Gross margin | — | — |
| Operating margin | −72.8% | −158.4% |
| Net margin | −52.0% | −165.6% |
| Free cash flow | −$73M | −$323M |
| Free cash flow margin | −33.6% | −187.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 8.3% | 1.2% |
| Last close | $31.83 | $9.45 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.6 million, sold $382,096 | sold $2.7 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
IDEAYA BiosciencesSyndax Pharmaceuticals
Operating margin
Percent of revenue
IDEAYA BiosciencesSyndax Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IDEAYA BiosciencesSyndax Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IDEAYA Biosciences and Syndax Pharmaceuticals pages.